Chevron CEO calls on Biden to stop suppressing the natural gas industry.
Chevron CEO Mike Wirth criticized US President Biden's natural gas policy, stating that it not only undermines the energy security of allies, but also slows down the progress in combating climate change. Wirth stated that the Biden administration should stop suppressing the natural gas industry.
Bristol Myers Says New Data From Phase 3 DAYBREAK Trial Showed Decreased Rates Of Brain Volume Loss Were Sustained In Open-label Extension For Patients Treated With Zeposia (Ozanimod) For Relapsing Forms Of Multiple Sclerosis
Chevron CEO Slams Biden LNG Export Pause as 'Undermining' Energy Security
What the Options Market Tells Us About Philip Morris Intl
What the Options Market Tells Us About Citigroup
10 Information Technology Stocks With Whale Alerts In Today's Session
Live On CNBC, Stephanie Link Announces Bought More Chipotle Mexican Grill, Bought Exxon Mobil
BTIG Waves the Caution Flag Around the Consumer Staples Sector
Wedbush Spotlights DELL, NVDA, MSFT, and Others as Rate Cuts Should Support the AI Trend
How to view the "historically pessimistic" oil price, goldman sachs: short but long!
Goldman Sachs expects that Brent crude oil will recover to $77 per barrel in the fourth quarter of this year, as the market's overly pessimistic sentiment towards oil demand improves and the OECD inventory remains slightly below normal levels, providing some support for oil prices. However, over time, the market's pessimistic expectations for supply and demand balance are gradually increasing, putting further pressure on oil prices next year.
Preview of US stocks | August retail sales data exceeds expectations, three major futures indices slightly rise; Bullish news frequently! Intel pre-market up nearly 7%.
Microsoft is giving out "red envelopes": dividend increase of 10%, planning to repurchase up to 60 billion US dollars; "New Fed Communication Agency" reiterated uncertainty: the magnitude of the first interest rate cut is still suspenseful.
Wall Street's Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 7% Dividend Yields
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
A Closer Look at Exxon Mobil's Options Market Dynamics
Citi Credit Card Delinquency Rate Edges Up, Charge-off Rate Retreats in August
10 Information Technology Stocks Whale Activity In Today's Session
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Bristol-Myers Squibb Analyst Ratings
Short Bets for Consumer Staples Rise in August Across Industries